文献速递前列腺癌

前列腺放疗后晚期泌尿生殖系统毒性的真实世界负担与管理:IRRADIaTE意大利登记研究

Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation.
PubMed 文献 · Eur Urol Oncol · 2026-01-24

IRRADIaTE是一项2024年启动的前瞻性、观察性、多中心登记研究,纳入20家意大利机构的321例局限性前列腺癌放疗后出现晚期(≥6个月)需急诊关注的泌尿生殖系统并发症的患者。结果显示43%入院时即为3-5级毒性,5年无住院生存率从86%降至42%,原发放疗组严重事件累积发生率更高。

要点

  • 前列腺放疗后晚期泌尿生殖毒性负担重,43%入院时即为3-5级事件。
  • 5年无住院生存率从86%降至42%,原发放疗组严重事件累积发生率更高。
  • 无需大手术治疗放疗相关并发症的患者比例从12个月的81%降至60个月的66%。

核心结论

  • 前列腺放疗后晚期泌尿生殖系统毒性显著且常需大量医疗资源。
  • 不同治疗设置间观察到的差异仅为相关性,不能推断因果机制或治疗效应。

研究设计与样本

  • 前瞻性、观察性、多中心登记研究,2024年启动,覆盖意大利20家机构。
  • 纳入321例局限性前列腺癌既往接受根治性、辅助或挽救性放疗后出现晚期(≥6个月)需急诊医疗关注的泌尿生殖系统并发症的男性。
  • 毒性分级采用不良事件通用术语标准,主要终点为3-5级事件的累积发生率(死亡为竞争风险)和自放疗完成起的无住院生存率。

主要发现

  • 321例患者中,50%接受原发放疗,50%接受前列腺切除术后放疗。
  • 入院时43%的患者表现为3-5级泌尿生殖系统毒性。
  • 5年内无住院生存率从86%下降至42%。
  • 原发放疗组观察到更高的严重事件累积发生率。
  • 无需大手术治疗放疗相关并发症的患者比例从放疗后12个月的81%(95%CI 76-97%)降至60个月的66%(95%CI 48-79%)。

临床怎么用

  • 临床应关注前列腺放疗后晚期泌尿生殖系统毒性,尤其是需急诊或住院的严重事件。
  • 原发放疗患者可能面临更高的严重事件累积风险,需加强随访和资源准备。

局限性

  • 不同放疗治疗设置间的基线年龄和合并症特征差异需予以承认。
  • 登记仅纳入出现并发症的男性,无法推断人群水平发生率或因果效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Radiotherapy (RT) is a key curative option for localized prostate cancer (PC). However, data on late genitourinary toxicity, especially adverse events requiring urgent care or hospitalization, remain limited. The aim of the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation (IRRADIaTE) is to characterize the burden and management of severe genitourinary adverse events following prostate RT across multiple high-volume centers in Italy. METHODS: A prospective, observational, multicenter registry was established in 2024 across 20 Italian institutions. Men with localized PC previously treated with curative, adjuvant, or salvage RT who presented with late (≥6 mo) genitourinary complications requiring urgent medical attention were enrolled. Demographics, treatment details, and outcomes were collected. Toxicity grading followed Common Terminology Criteria for Adverse Events. Primary endpoints were prespecified as (1) the cumulative incidence of grade 3-5 events with death as a competing risk and (2) hospitalization-free survival from RT completion. Analyses were descriptive and adjusted for prespecified confounders only. Key findings and limitations Among 321 patients, 50% received primary RT, and 50% postprostatectomy RT. At the time of admission, 43% presented with grade 3-5 genitourinary toxicity. Over 5 yr, the hospitalization-free survival rate declined from 86% to 42%. Higher cumulative incidence of severe events was observed in the primary RT group. The percentage of patients who did not require major surgery to manage RT-related complications decreased from 81% (95% confidence interval [CI] 76-97%) at 12 mo after RT to 66% (95% CI 48-79%) at 60 mo. Differences in baseline age and comorbidity profiles between the RT treatment settings must be acknowledged. Because the registry enrolls only men presenting with complications, population-level incidence and causal effects cannot be inferred. CONCLUSIONS AND CLINICAL IMPLICATIONS: Late genitourinary toxicity after prostate RT is substantial and often resource-intensive. Differences observed by treatment setting are associational; attribution of causal mechanisms and treatment effects requires dedicated causal-inference studies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bertolo R, Pastore AL, Verze P, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. 2026. PMID: 41582027. doi:10.1016/j.euo.2026.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。